IQVIA combines clinical research services with large-scale healthcare data analytics for life-science and healthcare clients. Formed from the combination of Quintiles and IMS Health, it runs late-stage trials, real-world evidence studies, and commercial analytics that track prescriptions, providers, and patient outcomes. Drug makers and biotech firms use IQVIA to design trials, recruit patients, and measure market performance after launch.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 4,017 | — | 266 | — |
| Q3 2025 | 4,100 | — | 331 | — |
| Q4 2025 | 4,364 | — | 514 | — |
| Q1 2026 | 4,151 | — | 274 | — |
| Q2 2026 | 4,368 | 8.7% | 256 | -3.8% |
All markets — KeepWinning global stock screener
Other companies on NYSE: HEICO Corporation (HEI), Fomento Económico Mexicano, S.A.B. de C.V. (FMX), Waters Corporation (WAT), JBS N.V. (JBS), Waste Connections, Inc. (WCN), American International Group, Inc. (AIG)